Jump to content
Powered by

Rentschler to focus on biotechnology

Rentschler, based in Laupheim, has sold all its Rentschler Pharma GmbH shares to RIEMSER AG in Greifswald/Isle of Riems. With this move, Rentschler is concentrating all its biotech activities at one site and thus providing the framework for further growth. All 100 Rentschler employees will retain their jobs and will be employed by Riemser Speciality Production GmbH in Greifswald.

Rentschler Pharma GmbH is a specialist in capsule and pellet technology with controlled drug release and will complement Riemser’s product spectrum of other solid medicines (tablets or coated tablets). The company will be managed by Dr. Peter Vogel. Riemser AG is a family-run company with four additional production sites in Germany. Over the last few years, the company has acquired numerous companies, patents and licences.

Another 14 million invested in the Laupheim site

Meanwhile, Rentschler is investing another 14 million euros in its Laupheim site. According to Rentschler, a logistics centre will be built and the administrative building in the Erwin-Rentschler-Straβe will be expanded. In the logistics centre there will be a high-rise warehouse, several cold stores, an incoming goods department, a dispatch area and the company’s transport fleet. The move into the new buildings is planned for the end of 2009.

In 2006, Rentschler sold its self-medication business. By concentrating on the development and production of biopharmaceuticals, the company hopes to benefit from high growth rates in this sector and hopes to achieve a sales growth of 40 per cent (up 58 million euros) for the 2008/2009 business year (as of 31st March).

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-to-focus-on-biotechnology